For the treatment of HIV infection, non-nucleoside reverse transcriptase inhibitors (NNRTIs) are used to prevent viral replication by binding to a pocket near the polymerase active site of HIV-1 reverse transcriptase.
At the ongoing ACS meeting in New Orleans, Rezubio Pharmaceuticals Co. Ltd. detailed the discovery and preclinical evaluation of novel small-molecule gut-restricted GPR40 agonists using membrane-anchored drug (MADD) design.
LX-101 from Lirum Therapeutics Inc. is an insulin-like growth factor 1 receptor (IGF-1R) inhibitor consisting of an IGF-1 variant coupled to a cytotoxic methotrexate payload. There are several aggressive cancer types of unmet need that have altered IGF-1R pathways and/or high IGF-1R expression, which correlates with poor prognosis.
To Steve Hyman, the manual that clinicians currently use to diagnose mental disorders is an active obstacle to getting a scientific understanding of those disorders. Hyman, who is director of the Stanley Center for Psychiatric Research at the Broad Institute, MIT and Harvard, and a former director of the National Institute of Mental Health (NIMH), listed multiple weaknesses of the American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders (DSM), whose diagnoses, he said, are “arbitrary, rigid, life-stage and context-insensitive,” as well as blind to the fact that mental disorders exist along a continuum.
Patients with amyotrophic lateral sclerosis (ALS) have a median survival of 2 to 5 years. There are 3 FDA-approved drugs for ALS (riluzole, edaravone and Relyvrio [phenylbuturate/taurursodiol]), but they only lead to modest benefit. There are several pathways involved in the disease, but all of them lead to neuroinflammation.
The use of latency reversing agents is useful for reducing the HIV reservoir, but their effect on infected cells isolated from untreated people with HIV is still unknown.
At this week’s ACS meeting in New Orleans, Fimbrion Therapeutics Inc. presented the rational design of a different series of small-molecule biaryl O- and C-linked mannoside-based inhibitors of the virulence factor FimH, as potential agents for the treatment of urinary tract infections (UTIs).
Medical Korea 2024 opened to a large audience in Seoul, South Korea for a two-day run to highlight advances in the medical field, including those in radiotherapy.
Recent studies have identified HAVCR2, which encodes immune checkpoint molecule TIM-3 (T-cell immunoglobulin mucin receptor 3), as a risk gene for late-onset Alzheimer’s disease (AD).
RSS
